Plasmacytoid urothelial carcinoma (PUC) is a rare, aggressive histologic variant of urothelial cancer characterised by a diffuse growth pattern and CDH1 mutation. We studied the efficacy of preoperative platinum-based chemotherapy in nonmetastatic PUC and immune checkpoint inhibitors (ICIs) in advanced PUC.
Cases of nonmetastatic PUC and advanced PUC treated with ICIs at our institution were identified. Outcomes were compared to those of a published cohort of patients with urothelial carcinoma not otherwise specified.
We identified 81 patients with nonmetastatic PUC. Of the patients with localised disease who underwent neoadjuvant chemotherapy, pathologic complete response and downstaging rates were 12 and 21%, respectively. Pathologic downstaging was not associated with significant improvement in clinical outcomes. Up to 18% of localised disease and 28% of locally advanced cases had unresectable disease at the time of surgery. ICI-treated advanced PUC (N = 21) had progression-free and overall survival of 4.5 and 10.5 months, respectively, and a 38% response rate. FGFR3 and DNA damage response gene alterations were observed in 3 and 15% of cases, respectively.
PUC is associated with high disease burden and poor chemosensitivity. Increased awareness and recognition of this disease variant will allow for new treatment strategies.
Subscribe to Journal
Get full journal access for 1 year
only $20.79 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M. & Reuter, V. E. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur. Urol. 70, 106–119 (2016).
Nigwekar, P., Tamboli, P., Amin, M. B., Osunkoya, A. O., Ben-Dor, D. & Amin, M. B. Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am. J. Surg. Pathol. 33, 417–424 (2009).
Kaimakliotis, H. Z., Monn, M. F., Cheng, L., Masterson, T. A., Cary, K. C., Pedrosa, J. A. et al. Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology 83, 1112–1116 (2014).
Al-Ahmadie, H. A., Iyer, G., Lee, B. H., Scott, S. N., Mehra, R., Bagrodia, A. et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat. Genet 48, 356–358 (2016).
Cockerill, P. A., Cheville, J. C., Boorjian, S. A., Blackburne, A., Thapa, P., Tarrell, R. F. et al. Outcomes following radical cystectomy for plasmacytoid urothelial carcinoma: defining the need for improved local cancer control. Urology 102, 143–147 (2017).
Li, Q., Assel, M., Benfante, N. E., Pietzak, E. J., Herr, H. W., Donat, M. et al. The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy. Eur. Urol. Focus 5, 104–108 (2019).
Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859–866 (2003).
Scosyrev, E., Ely, B. W., Messing, E. M., Speights, V. O., Grossman, H. B., Wood, D. P. et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 108, 693–699 (2011).
Kaimakliotis, H. Z., Monn, M. F., Cho, J. S., Pedrosa, J. A., Hahn, N. M., Albany, C. et al. Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology. Future Oncol. 12, 1795–1804 (2016).
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67–76 (2017).
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748–757 (2018).
Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P. et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. J. Clin. Oncol. 37, 1608–1616 (2019).
Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Luciano, R. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353–3360 (2018).
Powles, T., Kockx, M., Rodriguez-Vida, A., Duran, I., Crabb, S. J., Van Der Heijden, M. S. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706–1714 (2019).
Tully, C. M., Bochner, B. H., Dalbagni, G., Zabor, E. C., Herr, H. W., Donat, S. M. et al. Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND. J. Clin. Oncol. 32(4_suppl), 355 (2014).
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251–264 (2015).
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N. et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 47(D1), D941–D947 (2019).
Chang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155–163 (2016).
Chakravarty D., Gao J., Phillips S. M., Kundra R., Zhang H., Wang J. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. https://doi.org/10.1200/po.17.00011 (2017).
Iyer, G., Balar, A. V., Milowsky, M. I., Bochner, B. H., Dalbagni, G., Donat, S. M. et al. Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J. Clin. Oncol. 36, 1949–1956 (2018).
Teo, M. Y., Bambury, R. M., Zabor, E. C., Jordan, E., Al-Ahmadie, H., Boyd, M. E. et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin. Cancer Res 23, 3610–3618 (2017).
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540.e5–556.e5 (2017).
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 174, 1033 (2018).
Chung, A. D., Schieda, N., Flood, T. A., Cagiannos, I., Mai, K. T., Malone, S. et al. Plasmacytoid urothelial carcinoma (PUC): imaging features with histopathological correlation. Can. Urol. Assoc. J. 11, E50–E57 (2017).
Dayyani, F., Czerniak, B. A., Sircar, K., Munsell, M. F., Millikan, R. E., Dinney, C. P. et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J. Urol. 189, 1656–1661 (2013).
Keck, B., Wach, S., Stoehr, R., Kunath, F., Bertz, S., Lehmann, J. et al. Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer 13, 71 (2013).
Diamantopoulos, L. N., Khaki, A. R., Vakar-Lopez, F., Tretiakova, M. S., Gore, J. L., Schade, G. R. et al. Patient characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma. J. Clin. Oncol. 37, e16007 (2019).
Diamantopoulos, L. N., Khaki, A. R., Grivas, P., Gore, J. L., Schade, G. R., Hsieh, A. C. et al. Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes. Bladder Cancer 6, 71–81 (2020).
Liu, D., Plimack, E. R., Hoffman-Censits, J., Garraway, L. A., Bellmunt, J., Van Allen, E. et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. 2, 1094–1096 (2016).
Van Allen, E. M., Mouw, K. W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140–1153 (2014).
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).
Andrews, E., Curran, C., Grivas, P., Diamantopoulos, L. N., Drakaki, A., Jain, R. K. et al. Outcomes of advanced plasmacytoid urothelial carcinoma receiving systemic therapy. J. Clin. Oncol. 38, 580 (2020).
McGregor, B. A., Campbell, M. T., Xie, W., Farah, S., Bilen, M. A., Sonpavde, G. et al. Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers. J. Clin. Oncol. 38(15_suppl), 5018–5018 (2020).
Ramamurthy, C., Arguello, D., Anari, F., Ghatalia, P., Zibelman, M. R., Plimack, E. R. et al. Molecular profiling of aggressive variant urothelial carcinoma. J. Clin. Oncol. 37(7_suppl), 378 (2019).
Reis, H., Serrette, R., Posada, J., Lu, V., Chen, Y. B., Gopalan, A. et al. PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among 3 commonly used and commercially available antibodies. Am. J. Surg. Pathol. 43, 920–927 (2019).
Sara DiNapoli provided editorial support for this manuscript.
Ethics approval and consent to participate
This study was approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board (#17–214). The need for informed consent was waived by the institutional review board. This study was performed in accordance with the Declaration of Helsinki.
Anonymised data will be provided upon request.
MYT has received Research Support from Bristol Myers Squibb, Clovis and Pharmacyclics; DBS has consulted with/received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, BridgeBio, Vividion Therapeutics, Scorpion Therapeutics and Illumina; SAF has received research support from AstraZeneca, Genentech/Roche, is a consultant/advisory board member for Merck, and owns stock in Urogen, Allogene Therapeutics, Neogene Therapeutics, Kronos Bio, and Inconovir; DFB has received research funding from Novartis, has received personal fees from Merck Sharp & Dohme, Eisai, Fidia Farmaceutici S.p.A., Lilly, and UroGen Pharma; and has received grants and personal fees from Bristol‐Myers Squibb, Roche/Genentech, and Novartis; and grants from Dendreon; GVI has received personal fees from Mirati Therapeutics and Janssen and research support from Novartis; JER has consulted for AstraZeneca, Bayer, Merck, BMS, Roche, Genentech, Seattle Genetics, Astellas, Boehringher Ingelheim, GSK, Mirati, Janssen, Lilly, and Pfizer. He has also received funding for clinical trials from Roche/Genentech, AstraZeneca, Bayer, Seattle Genetics and Astellas.
This work was supported in part by the National Cancer Institute at the National Institutes of Health [P30 CA008748 to Memorial Sloan Kettering Cancer Center].
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Teo, M.Y., Al-Ahmadie, H., Seier, K. et al. Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. Br J Cancer (2021). https://doi.org/10.1038/s41416-020-01244-2